Literature DB >> 17238827

Pegylation of IFN-alpha and antiviral activity.

Anne Boulestin1, Nassim Kamar, Karine Sandres-Sauné, Laurent Alric, Jean-Pierre Vinel, Lionel Rostaing, Jacques Izopet.   

Abstract

The development of pegylated interferons (PEG-IFN) has significantly improved the eradication rates in patients with chronic hepatitis C. Two forms of PEG-IFN have been developed, based on two pegylation chemistries: the 12-kDa linear PEG-IFN-alpha2b and the 40-kDa branched PEG-IFN-alpha2a. We compared the in vitro antiviral activity of linear and branched PEG-IFN using the vesicular stomatitis virus (VSV) cytopathic effect (CPE) reduction assay. The specific antiviral activity of branched PEG-IFN was 7% of that of linear PEG-IFN. A given quantity of linear and of branched PEG-IFN does not represent the same biologic activity. A bioassay could give new insights to compare the pharmacokinetic profile of linear PEG-IFN and of branched PEG-IFN.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17238827     DOI： 10.1089/jir.2006.26.849

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN： 1079-9907            Impact factor:   2.607


  4 in total

1.  Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.

Authors:  Yanelda García-Vega; Idrian García-García; Sonia E Collazo-Caballero; Egla E Santely-Pravia; Alieski Cruz-Ramírez; Angela D Tuero-Iglesias; Cristian Alfonso-Alvarado; Mileidys Cabrera-Placeres; Nailet Castro-Basart; Yaquelín Duncan-Roberts; Tania I Carballo-Treto; Josanne Soto-Matos; Yoandy Izquierdo-Toledo; Dania Vázquez-Blomquist; Elizeth García-Iglesias; Iraldo Bello-Rivero
Journal:  BMC Pharmacol Toxicol       Date:  2012-12-28       Impact factor: 2.483

2.  Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.

Authors:  Idrian García-García; Carlos A González-Delgado; Carmen M Valenzuela-Silva; Alina Díaz-Machado; Marisol Cruz-Díaz; Hugo Nodarse-Cuní; Orlando Pérez-Pérez; Cimara H Bermúdez-Badell; Joel Ferrero-Bibilonia; Rolando Páez-Meireles; Iraldo Bello-Rivero; Fidel R Castro-Odio; Pedro A López-Saura
Journal:  BMC Pharmacol       Date:  2010-11-23

3.  Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.

Authors:  Idrian García-García; Ignacio Hernández-González; Alina Díaz-Machado; Carlos A González-Delgado; Sonia Pérez-Rodríguez; Yanelda García-Vega; Rosario Campos-Mojena; Ángela D Tuero-Iglesias; Carmen M Valenzuela-Silva; Alieski Cruz-Ramírez; Alis Martín-Trujillo; Héctor Santana-Milián; Pedro A López-Saura; Iraldo Bello-Rivero
Journal:  BMC Pharmacol Toxicol       Date:  2016-12-07       Impact factor: 2.483

4.  Oral Pharmacokinetics of a Chitosan-Based Nano- Drug Delivery System of Interferon Alpha.

Authors:  Julieta C Imperiale; Inbar Schlachet; Marianela Lewicki; Alejandro Sosnik; Mirna M Biglione
Journal:  Polymers (Basel)       Date:  2019-11-11       Impact factor: 4.329
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.